---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073502"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:58:01.878070+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics reports 2025 net revenue $154.9M, up 7.4%; issues 2026 guidance $173-183M

## Summary
- Full-year 2025 net revenue $154.9M (+7.4% YoY); Q4 net revenue $40.6M (-0.5% vs Q4 2024).
- Acute care franchise grew 65.1% to $49.6M; ZYNRELEF +49%, APONVIE +156%.
- Oncology franchise declined 7.8% to $105.3M; CINVANTI -3.3%, SUSTOL -39.9%.
- 2026 guidance: net revenue $173-183M, adjusted EBITDA $10-20M.
- Cash $46.6M; ZYNRELEF J-code effective Oct 2025; prefilled syringe FDA target mid-to-late 2027.

## SEC filing metadata
- accession: 0001193125-26-073502
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/0001193125-26-073502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073502
- JSON: https://secwatch.observer/filing/0001193125-26-073502.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.